Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
McKesson
Baxter
Boehringer Ingelheim
McKinsey

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021770

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

NDA 021770 describes ALPHAGAN P, which is a drug marketed by Allergan and is included in two NDAs. It is available from one supplier. There are eight patents protecting this drug and two Paragraph IV challenges. Additional details are available on the ALPHAGAN P profile page.

The generic ingredient in ALPHAGAN P is brimonidine tartrate. There are eleven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.
Summary for 021770
Tradename:ALPHAGAN P
Applicant:Allergan
Ingredient:brimonidine tartrate
Patents:8
Pharmacology for NDA: 021770
Mechanism of ActionAdrenergic alpha-Agonists
Medical Subject Heading (MeSH) Categories for 021770
Suppliers and Packaging for NDA: 021770
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ALPHAGAN P brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 021770 NDA Allergan, Inc. 0023-9321 0023-9321-03 1 BOTTLE, DROPPER in 1 CARTON (0023-9321-03) > 3 mL in 1 BOTTLE, DROPPER
ALPHAGAN P brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 021770 NDA Allergan, Inc. 0023-9321 0023-9321-05 1 BOTTLE, DROPPER in 1 CARTON (0023-9321-05) > 5 mL in 1 BOTTLE, DROPPER
Paragraph IV (Patent) Challenges for 021770
Tradename Dosage Ingredient NDA Submissiondate
ALPHAGAN P SOLUTION/DROPS;OPHTHALMIC brimonidine tartrate 021770 2006-12-20

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION/DROPS;OPHTHALMICStrength0.1%
Approval Date:Aug 19, 2005TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Jul 10, 2021Product Flag?YSubstance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Jan 10, 2022Product Flag?Substance Flag?Delist Request?Y
Patent:  Start TrialPatent Expiration:Jan 18, 2022Product Flag?Substance Flag?Delist Request?Y

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Medtronic
Baxter
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.